Logo image of ALECR.PA

EUROFINS CEREP-REGR (ALECR.PA) Stock Fundamental Analysis

EPA:ALECR - Euronext Paris - Matif - FR0013256518 - Common Stock - Currency: EUR

17600  -700 (-3.83%)

Fundamental Rating

5

Taking everything into account, ALECR scores 5 out of 10 in our fundamental rating. ALECR was compared to 18 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making ALECR a very profitable company, without any liquidiy or solvency issues. ALECR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

ALECR had positive earnings in the past year.
ALECR had positive earnings in each of the past 5 years.
In the past 5 years ALECR always reported negative operating cash flow.
ALECR.PA Yearly Net Income VS EBIT VS OCF VS FCFALECR.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M 4M 6M 8M 10M

1.2 Ratios

ALECR has a Return On Assets of 9.29%. This is amongst the best in the industry. ALECR outperforms 94.44% of its industry peers.
ALECR's Return On Equity of 10.82% is amongst the best of the industry. ALECR outperforms 88.89% of its industry peers.
ALECR has a Return On Invested Capital (5.81%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for ALECR is significantly above the industry average of 6.95%.
The last Return On Invested Capital (5.81%) for ALECR is well below the 3 year average (12.61%), which needs to be investigated, but indicates that ALECR had better years and this may not be a problem.
Industry RankSector Rank
ROA 9.29%
ROE 10.82%
ROIC 5.81%
ROA(3y)14.35%
ROA(5y)13.22%
ROE(3y)18.17%
ROE(5y)17.04%
ROIC(3y)12.61%
ROIC(5y)11.68%
ALECR.PA Yearly ROA, ROE, ROICALECR.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 5 10 15 20

1.3 Margins

With an excellent Profit Margin value of 16.86%, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of ALECR has grown nicely.
ALECR has a Operating Margin (12.72%) which is comparable to the rest of the industry.
ALECR's Operating Margin has improved in the last couple of years.
ALECR has a Gross Margin of 85.67%. This is amongst the best in the industry. ALECR outperforms 100.00% of its industry peers.
In the last couple of years the Gross Margin of ALECR has grown nicely.
Industry RankSector Rank
OM 12.72%
PM (TTM) 16.86%
GM 85.67%
OM growth 3Y-4.67%
OM growth 5Y4.73%
PM growth 3Y0.56%
PM growth 5Y2.75%
GM growth 3Y20.58%
GM growth 5Y11.57%
ALECR.PA Yearly Profit, Operating, Gross MarginsALECR.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 20 40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

ALECR has about the same amout of shares outstanding than it did 1 year ago.
ALECR has more shares outstanding than it did 5 years ago.
ALECR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALECR.PA Yearly Shares OutstandingALECR.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2K 4K 6K 8K
ALECR.PA Yearly Total Debt VS Total AssetsALECR.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

An Altman-Z score of 12.28 indicates that ALECR is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 12.28, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
ALECR has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ALECR has a better Debt to Equity ratio (0.00) than 100.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.28
ROIC/WACCN/A
WACCN/A
ALECR.PA Yearly LT Debt VS Equity VS FCFALECR.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 7.27 indicates that ALECR has no problem at all paying its short term obligations.
With an excellent Current ratio value of 7.27, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
A Quick Ratio of 6.83 indicates that ALECR has no problem at all paying its short term obligations.
ALECR has a better Quick ratio (6.83) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 7.27
Quick Ratio 6.83
ALECR.PA Yearly Current Assets VS Current LiabilitesALECR.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

ALECR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.28%.
The Earnings Per Share has been decreasing by -0.04% on average over the past years.
The Revenue has decreased by -6.85% in the past year.
The Revenue has been growing by 11.57% on average over the past years. This is quite good.
EPS 1Y (TTM)-21.28%
EPS 3Y-11.62%
EPS 5Y-0.04%
EPS Q2Q%-12.19%
Revenue 1Y (TTM)-6.85%
Revenue growth 3Y10.44%
Revenue growth 5Y11.57%
Sales Q2Q%-7.12%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALECR.PA Yearly Revenue VS EstimatesALECR.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 24.28, which indicates a rather expensive current valuation of ALECR.
ALECR's Price/Earnings ratio is a bit cheaper when compared to the industry. ALECR is cheaper than 61.11% of the companies in the same industry.
When comparing the Price/Earnings ratio of ALECR to the average of the S&P500 Index (26.48), we can say ALECR is valued inline with the index average.
Industry RankSector Rank
PE 24.28
Fwd PE N/A
ALECR.PA Price Earnings VS Forward Price EarningsALECR.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALECR.PA Per share dataALECR.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2K 4K 6K

4.3 Compensation for Growth

The excellent profitability rating of ALECR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALECR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUROFINS CEREP-REGR

EPA:ALECR (8/4/2025, 7:00:00 PM)

17600

-700 (-3.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap176.00M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 24.28
Fwd PE N/A
P/S 4.09
P/FCF N/A
P/OCF N/A
P/B 2.63
P/tB 2.72
EV/EBITDA N/A
EPS(TTM)725
EY4.12%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4300
BVpS6700
TBVpS6476
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 9.29%
ROE 10.82%
ROCE 7.94%
ROIC 5.81%
ROICexc 5.81%
ROICexgc 6%
OM 12.72%
PM (TTM) 16.86%
GM 85.67%
FCFM N/A
ROA(3y)14.35%
ROA(5y)13.22%
ROE(3y)18.17%
ROE(5y)17.04%
ROIC(3y)12.61%
ROIC(5y)11.68%
ROICexc(3y)14.13%
ROICexc(5y)13.15%
ROICexgc(3y)14.81%
ROICexgc(5y)13.93%
ROCE(3y)17.15%
ROCE(5y)15.9%
ROICexcg growth 3Y-17.85%
ROICexcg growth 5Y-1.82%
ROICexc growth 3Y-16.84%
ROICexc growth 5Y-2.29%
OM growth 3Y-4.67%
OM growth 5Y4.73%
PM growth 3Y0.56%
PM growth 5Y2.75%
GM growth 3Y20.58%
GM growth 5Y11.57%
F-ScoreN/A
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.27
Quick Ratio 6.83
Altman-Z 12.28
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.28%
EPS 3Y-11.62%
EPS 5Y-0.04%
EPS Q2Q%-12.19%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.85%
Revenue growth 3Y10.44%
Revenue growth 5Y11.57%
Sales Q2Q%-7.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.62%
EBIT growth 3Y5.28%
EBIT growth 5Y16.84%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A